Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.
Building on its core competencies in clinical development, regulatory affairs and commercialization of innovative anti-cancer agents, Clovis intends to license or acquire rights to oncology compounds in all stages of clinical development.
Clovis intends to target development programs at specific subsets of cancer populations, and will simultaneously develop diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 05/01/09 | Series A | 146M | Frazier Healthcare Ventures, Domain Associates, ProQuest Investments, Versant Ventures, Aberdare Ventures, Abingworth, New Enterprise Associates | Unknown |
People
Patrick J. Mahaffy (President, CEO)
Andrew R. Allen (EVP, CMO)
Gillian C. Ivers-Read (EVP, Regulatory Affairs and Technical Operations)
M. James Barrett (Board Member)
Brian G. Atwood (Board Member)
Competitors
Oncologic:
Oncologic has developed a proprietary anti-cancer technology anticipated to give CURE rates of approximately 90% for… See Company Profile »